ASBPW · Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings has taken a significant strategic step by entering into a non-binding letter of intent to acquire the Driver Controls Systems business unit from Firefish Topco, LLC. The proposed $30.0 million cash transaction represents a material expansion beyond the company's biopharma focus into automotive controls systems. The structure involves acquiring 100% of equity, assets, and liabilities through a combination of stock and asset transactions, though specific details remain to be negotiated. Key protective provisions include a $3.5 million break-up fee that creates financial consequences for either party failing to proceed in good faith, and a 30-day exclusivity period that prevents sellers from shopping the business to other potential buyers. The company has indicated it does not anticipate needing new equity financing to complete the purchase, suggesting it plans to use existing resources. Importantly, the LOI is explicitly non-binding except for specific provisions, meaning the acquisition remains contingent on successful negotiation of definitive agreements and satisfaction of closing conditions. The company's post-acquisition plan to engage Lakewood & Company for management services indicates a recognition of the need for specialized automotive industry expertise to operate the acquired business successfully.